Society for Immunotherapy of Cancer (SITC)
November 9-14, 2020
Significant anti-tumor activity of HBI-8000, a class I histone deacetylase inhibitor (HDACi) in combination with nivolumab (NIVO) in anti-PD1 therapy-naïve advanced melanoma (TN-Mel)
American Heart Association (AHA) Scientific Sessions
November 16-18, 2019
HBI-3000: A Novel Drug for Conversion of Atrial Fibrillation
– Phase 1 Study Results
Society for Immunotherapy of Cancer (SITC)
November 7-11, 2018
A Phase 1b/2 Study of the Safety and Efficacy of HBI-8000-Nivolumab Combination in
Melanoma (MEL), Renal Cell Carcinoma (RCC) and Non-Small Cell Lung Cancer (NSCLC)
T Cell Lymphoma Forum (TCLF)
Jan 28-30, 2016
Induction of cell death by HBI-8000, an HDAC inhibitor, in adult T-cell leukemia/lymphoma (ATL) is associated with activation of Bim and NLRP
International Cancer Immunotherapy (ICI)
August 21–26, 2016
The HDAC inhibitor HBI-8000 enhances immunotherapy with either PD-1 or PD-L1 blockade in the MC38 and 4T1 models of colon cancer
American Society of Hematology (ASH)
December 3-6, 2016
Oral HDAC Inhibitor HBI-8000 in Japanese Patients with Non–Hodgkin Lymphoma (NHL): Phase I Safety and Efficacy Results
